PAA 2022 , Human Trials , Covid , MND , Oncology , HVTL-1, K9 Phase III, page-1334

Agree with JTG thats these are 2 separate discussions and i guess to put it in perspective imagine being across the table from Vet Major's heavies and in deep, serious and aggressive discussions about the value of the canine license and then we throw in a curve ball saying we want more/or our asking price is more because we have seen favorable results from the recent MND trial in humans.

Quite frankly i think they would laugh us out of the room. The canine commercialisation should be able to sell its self with favorable results. The biggest concern to me is, is the current management capable of driving the negotiations to ensure the most favorable outcome for all stakeholders, primarily SHs.

We can only hope.

PS: Come on Anusha, do your thing and put your stamp on a PAA price sensitive announcement....why are we waiting!!!